Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021–January 2022
Brechje de Gier, Liselotte van Asten, Tjarda M. Boere, et al.
Vaccine (2023) Vol. 41, Iss. 31, pp. 4488-4496
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023
C. Henri van Werkhoven, Anne-Wil Valk, Bente Smagge, et al.
Eurosurveillance (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 41
Review: N1-methyl-pseudouridine (m1Ψ): Friend or foe of cancer?
Alberto Rubio‐Casillas, David E. Cowley, Mikolaj Raszek, et al.
International Journal of Biological Macromolecules (2024) Vol. 267, pp. 131427-131427
Closed Access | Times Cited: 8
Impact of COVID-19 vaccination on lower urinary tract (LUTS) in benign prostatic hyperplasia (BPH) patients
Amirreza Shamshirgaran, Diana Taheri, Seyed Reza Yahyazadeh, et al.
Clinical and Experimental Vaccine Research (2025) Vol. 14, Iss. 1, pp. 44-44
Open Access
The impact of public healthcare system on COVID-19 mortality rate in selected European and South Caucasian countries
Gaetano Perone
Eurasian economic review (2025)
Closed Access
Determinants of COVID-19 Vaccine Uptake in The Netherlands: A Nationwide Registry-Based Study
Joyce Pijpers, Annika van Roon, Caren van Roekel, et al.
Vaccines (2023) Vol. 11, Iss. 9, pp. 1409-1409
Open Access | Times Cited: 9
SARS‐CoV‐2 Seroprevalence Trends in the Netherlands in the Variant of Concern Era: Input for Future Response
Eric R. A. Vos, Cheyenne C. E. van Hagen, Denise Wong, et al.
Influenza and Other Respiratory Viruses (2024) Vol. 18, Iss. 6
Open Access | Times Cited: 1
The Platform Trial in COVID-19 Priming and BOOsting (PICOBOO): The Immunogenicity, Reactogenicity, and Safety of Licensed COVID-19 Vaccinations Administered as a Second Booster in BNT162b2 Primed Individuals Aged 18-<50 and 50-<70 Years Old
Charlie McLeod, Michael Dymock, Katie L. Flanagan, et al.
(2024)
Closed Access | Times Cited: 1
Risk of death and cardiovascular events following COVID-19 vaccination or positive SARS-CoV-2 test amongst adult Singaporeans during omicron transmission
Liang En Wee, Muhammad Ismail Bin Abdul Malek, Janice Ser Huey Tan, et al.
Vaccine (2024) Vol. 42, Iss. 26, pp. 126356-126356
Closed Access | Times Cited: 1
Vaccine Hesitancy and Associated Factors Amongst Health Professionals: A Scoping Review of the Published Literature
Antonios Christodoulakis, Izolde Bouloukaki, Antonia Aravantinou-Karlatou, et al.
Vaccines (2024) Vol. 12, Iss. 12, pp. 1411-1411
Open Access | Times Cited: 1
Number of COVID-19 hospitalisations averted by vaccination: Estimates for the Netherlands, January 6, 2021 through August 30, 2022
Senna C.J.L. van Iersel, Scott McDonald, Brechje de Gier, et al.
Vaccine (2023) Vol. 41, Iss. 26, pp. 3847-3854
Open Access | Times Cited: 4
Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalization and ICU admission, the Netherlands, 9 October - 5 December 2023
C. Henri van Werkhoven, Anne-Wil Valk, Bente Smagge, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 4
Myocarditis Associated with COVID-19 Vaccination
Kamila Florek, Mateusz Sokolski
Vaccines (2024) Vol. 12, Iss. 10, pp. 1193-1193
Open Access | Times Cited: 1
Nationwide SARS-CoV-2 Seroprevalence Trends in the Netherlands in the Variant of Concern Era, 2021-2022: an Ongoing Prospective Cohort Study
Eric R. A. Vos, Cheyenne C. E. van Hagen, Denise Wong, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Performance of a Point-of-Care Fluorescence Immunoassay Test to Measure the Anti-Severe Acute Respiratory Syndrome Corona Virus 2 Spike, Receptor Binding Domain Antibody Level
Marita Restie Tiara, Hofiya Djauhari, Febi Ramdhani Rachman, et al.
Diagnostics (2023) Vol. 13, Iss. 24, pp. 3686-3686
Open Access | Times Cited: 3
Performance of A Point-of-care Fluorescence Immunoassay Test to measure anti Severe Acute Respiratory Syndrome Corona Virus 2 Spike, Receptor Binding Domain Antibody Level
Marita Restie Tiara, Hofiya Djauhari, Febi Ramdhani Rachman, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Sociodemographic Inequalities in COVID-19 Booster Dose Vaccination Coverage: a Retrospective Study of 196 Provinces in Peru
Claudio Intimayta‐Escalante, Gustavo Tapia-Sequeiros, Daniel Rojas‐Bolivar
Journal of Racial and Ethnic Health Disparities (2024)
Closed Access
The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old.
Caroline Mcleod, Dymock, Katie L. Flanagan, et al.
Journal of Infection (2024), pp. 106286-106286
Open Access
CMV Retinitis in the Context of SARS-CoV-2 Infection: A Case Study and Comprehensive Review of Viral Interactions
Emil Robert Stoicescu, Laura Andreea Ghenciu, Roxana Iacob, et al.
Pathogens (2024) Vol. 13, Iss. 11, pp. 938-938
Open Access
Biases in COVID-19 vaccine effectiveness studies using cohort design
Suneth Agampodi, Birkneh Tilahun Tadesse, Sushant Sahastrabuddhe, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access
Modeling the SARS-CoV-2 Epidemic and the Efficacy of Different Vaccines Across Different Network Structures
Gregg Hartvigsen, Yannis Dimitroff
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old.
Caroline Mcleod, Michael Dymock, Katie L. Flanagan, et al.
Journal of Infection (2024) Vol. 89, Iss. 6, pp. 106346-106346
Open Access
Excess mortality during the first two years of the COVID-19 epidemic (2020-2021) in the Netherlands: overall and across demographic subgroups
Camila Caram‐Deelder, Astrid van Hylckama Vlieg, Rolf H. H. Groenwold, et al.
IJID Regions (2024) Vol. 14, pp. 100500-100500
Open Access
COVID-19 vaccination and short-term mortality risk: a nationwide self-controlled case series study in The Netherlands
Isabel Slurink, Annemarijn R. de Boer, Marc J. M. Bonten, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
The challenge of normalizing vaccine behaviors in the postpandemic era
Christina Wiesmann, Brian Conway
AIDS (2024) Vol. 39, Iss. 2, pp. 206-207
Closed Access
COVID-19 mRNA-vaccination and all-cause mortality in the adult population in Norway during 2021-2023: a population-based cohort study
Jesper Dahl, German Tapia, Håkon Bøas, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Page 1 - Next Page

Scroll to top